Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy.

Pharmaceuticals (Basel) · 2025 · PMC12736081 · PMID 41471300

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significancep = 0.08so close (0.05 < p ≤ 0.1)

In the brolucizumab group, BCVA improved from 0.35 ± 0.26 at baseline to 0.29 ± 0.27 at the 3-month visit, but the change did not reach statistical significance ( p = 0.08).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.